NeuroSense Therapeutics Stock Forum

$NeuroSense Therapeutics (NRSN.US)$ In connection with the offering, NeuroSense agreed to sell an aggregate of 4,000,000 ordinary shares (or ordinary share equivalents) and 8,000,000 warrants to purchase an aggregate of 8,000,000 ordinary shares, at a combined purchase price of $1.25 per share and two accompanying warrants, representing a purchase price of 25% above the closing pricing of NeuroSense's ordinary shares on November 29, 2024. The warrants have a term of five ye...

$NeuroSense Therapeutics (NRSN.US)$ Reuters· 2 mins ago
Neurosense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
Monday, 2nd December at 8:30 am
CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with a single investor and with NeuroSense's Chief Executive Office...

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NeuroSense Therapeutics (NASDAQ: NRSN) has secured a Type C meeting with the FDA on November 6, 2024, to discuss the design of its Phase 3 clinical trial for PrimeC, a potential ALS treatment. The meeting will focus on finalizing trial design and reviewing NDA submission readiness.
PrimeC has demonstrated significant results in reducing disease progression markers. The co...

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
NeuroSense Therapeutics (Nasdaq: NRSN) has provided an update on its plans to file for early commercialization approval for PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. The company plans to submit its dossier in Q2 2025, with an expected regulatory decision by Q1 2026.
The submissi...

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 4...

$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

$NeuroSense Therapeutics (NRSN.US)$ Reuters· 3 mins ago
Neurosense Therapeutics Granted Key U.S. Patent for Novel Primec Formulation, Its Lead Asset for ALS and Alzheimer's

$NeuroSense Therapeutics (NRSN.US)$ NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) on Wednesday said it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS).
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, mile...